Crossmark

Resolving genetic heterogeneity in cancer

Crossref DOI link: https://doi.org/10.1038/s41576-019-0114-6

Published Online: 2019-03-27

Published Print: 2019-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Turajlic, Samra

Sottoriva, Andrea https://orcid.org/0000-0001-6709-9533
Graham, Trevor https://orcid.org/0000-0001-9582-1597
Swanton, Charles https://orcid.org/0000-0002-4299-3018
License Information

Text and Data Mining valid from 2019-03-27
More Information

Article History

First Online: 27 March 2019

Change Date: 28 October 2019

Change Type: Correction

Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Competing interests

: C.S. reports grant support from Cancer Research UK, UCLH Biomedical Research Council, the Rosetrees Trust and AstraZeneca. C.S. has received personal fees from Boehringer Ingelheim, Novartis, Eli Lilly, Roche Ventana, GlaxoSmithKline, Pfizer, Genentech and Celgene. C.S. also reports stock options in GRAIL, APOGEN Biotechnologies and EPIC Bioscience and has stock options and is co-founder of Achilles Therapeutics. S.T. reports grant support from Cancer Research UK, RMH/ICR Biomedical Research Council and Ventana. S.T. also reports speaking fees from Ventana, outside the submitted work, and has a patent on indel burden and checkpoint inhibitor response filed and a patent on targeting of frameshift neo-antigens for personalized immunotherapy filed. A.S. and T.G. declare no competing interests.